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Abstract
Purpose This study reevaluates the potential role of dif-
ferent tumour markers as prognostic indicators in untreated
nephroblastoma.
Methods Expression of a broad panel of tumour markers
was investigated by means of immunohistochemical anal-
ysis in 43 WT patients. Patients were treated by radical
nephrectomy and had a mean follow-up of 11.9 years.
Results Generally, all the tumour markers studied were
expressed in normal kidney tissue and at variable levels in
the three cell types of WT (blastema, epithelium and
stroma). Immunoreactive blastemal (Bcl-X, Bcl-2 and
CD44s) and epithelial (Bcl-X, Bcl-2 and MIB-1) cells were
present in the majority of tumours. No correlation was
found between their expression and pathological stages.
Univariate analysis showed that blastemal WT-1, TGF-a,
VEGF, MIB-1 and p27 Kip1 were indicative for clinical
progression. In a multivariate analysis, WT-1 protein
expression by blastemal cells was an independent prog-
nostic marker for clinical progression.
Conclusions The blastemal WT-1, TGF-a, VEGF, MIB-1
and p27Kip1 expression correlate with clinical progression
in untreated nephroblastoma. Therefore, their expression
may be of value in identifying patients with a high pro-
pensity to develop distant metastases.
Keywords Wilms’ tumour  Immunohistochemsitry 
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Introduction
Wilms’ tumour (WT) is one of the most common solid
tumours in children, with a frequency of 1 in 10,000 live
births. The most important predictors of treatment failure
for children with WT are tumour histology and stage of
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disease, both of which are used to stratify patients to select
appropriate modern therapeutic protocols [1, 2]. The use of
preoperative chemotherapy for WT has become increas-
ingly popular. The International Society of Paediatric
Oncology (SIOP) in Europe showed that preoperative
therapy facilitated surgery and reduced the frequency of
tumour spillage at the time of surgery with good survival
outcome [3]. An assumption of the SIOP trials has been
that preoperative chemotherapy does not significantly
obscure important histopathologic parameters [4, 5].
The SIOP approach is different from that of the National
Wilms’ Tumour Study (NWTS) which does not apply
routine preoperative treatment. NWTS investigators
believe that preoperative treatment may compromise his-
tological evaluation of the tumour, as well as obscuring
tumour stage. Thereby, the ability to optimize subsequent
therapy for the appropriate stage and histological type of
each patient is compromised as well [6]. However, limited
published data are available to give insight into possible
differences in the expression patterns of tumour markers in
tumours of patients receiving chemotherapy and those who
did not. Our survey encompasses the study of a broad panel
of tumour markers linked with the biological behaviour of
WT. Also, during the course of this study, the research was
focused on increasing our knowledge of the expression of
various markers and their localization in the tumour and on
the selection of markers that might be of prognostic value.
In previous studies based on groups of nephroblastoma
patients preoperatively treated by chemotherapy, a signif-
icant correlation was found between the expression of
blastemal WT-1, TGF-a, Bcl-2, CD44v5, VEGF, FLT-1,
MIB-1 and p27kip-1 and clinical progression [7–12].
The purpose of the present study is to reevaluate the
expression patterns and the prognostic significance of these
tumour markers in a group of preoperatively untreated
nephroblastomas and to investigate the effect of chemo-
therapeutical pretreatment, using immunohistochemistry in
paraffin-embedded material. The discussion comments on
statistical phenomena that explains the substantial differ-
ences in the results reported here compared with those
results obtained with studies of chemotherapeutically pre-
treated patients with classical nephroblastoma which did
not display any anaplastic features (Table 1).
Patients and methods
Patients and sample selection
Forty-three patients with nephroblastoma were treated by
tumour nephrectomy and subsequently by chemotherapy,
according to the NWTS protocol. All nephrectomy speci-
mens were fixed in 10% buffered formalin and embedded
in paraffin. Tumour staging was done according to the
National Wilms’ Tumour Staging System [13]. But, the
tumour histopathology was assigned according to the
adaptation of the revised SIOP working classification of
renal tumour of childhood (2001) [14]. Clinical progression
was defined as histologically or cytologically proven local
recurrence or the appearance of distant metastases. Tumour
death was defined as death due to direct effect of
metastases.
Clinicopathological data of preoperatively treated
Wilms’ tumour
In the published work on WT-1, Bcl-2, Bax, and Bcl-X and
CD44 isoforms [7, 9, 10], 61 patients were studied. Clinical
progression occurred in 14 patients (23%), and eight
patients (13%) died from their tumour. The pT-stage dis-
tribution was T1 in 21, T2 in 20 and T3 in 20 patients.
While, in the published work on EGF-R, TGF-a, cerbB-2,
VEGF and Flt-1 and MIB-1 and p27Kip1 [8, 11, 12], 62
patients with nephroblastoma were studied. Clinical pro-
gression occurred in 14 patients (23%). Seven patients
(11%) died from their tumour. The pT-stage distribution
was T1 in 22, T2 in 19 and T3 in 21 patients (Table 1).
Table 1 Expression of antigens factors in preoperatively treated and
untreated Wilms’ tumour (WT) patients
Antigen % of positive cases
Untreated WT Treated WT [7–12]
Blastema Epithelial Blastema Epithelial
CD44 isoforms
CD44s 28 (65%) 24 (56%) 38 (62%) 47 (77%)
CDD44v5 23 (54%) 17 (40%) 27 (44%) 37 (61%)
CD44v10 21 (49%) 16 (37%) 25 (41%) 25 (41%)
Apoptosis-associated markers
Bcl-2 34 (79%) 31 (72%) 32 (53%) 33 (54%)
Bax 21 (49%) 18 (42%) 25 (41%) 27 (44%)
Bcl-X 38 (88%) 34 (79%) 23 (38%) 35 (57%)
Growth factors
TGF-a 21 (49%) 24 (56%) 30 (48%) 31 (50%)
C-erbB2 21 (49%) 26 (61%) 21 (34%) 33 (53%)
VEGF 23 (54%) 26 (61%) 32 (52%) 38 (61%)
Growth factor receptors
EGF-R 22 (51%) 25 (58%) 27 (44%) 37 (60%)
Flt-1 22 (51%) 20 (47%) 29 (47%) 35 (57%)
Tumour suppressor genes
WT-1 20 (47%) 26 (61%) 36 (59%) 35 (57%)
P27Kip-1 18 (42%) 18 (42%) 35 (57%) 45 (73%)
Proliferation marker
MIB-1 23 (54%) 28 (65%) 38 (61%) 41 (66%)
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All the patients were preoperatively treated by neo-
adjuvant chemotherapy and subsequent tumour nephrec-
tomy. The blastemal cells presented after chemotherapy
formed only small foci of blastema. The mean overall
follow-up period of both groups was 5.7 years.
Immunohistochemistry
The PAP (peroxidase-anti-peroxidase) technique was used,
which described briefly by Ghanem et al. [7–12]. The studied
tumour marker included [CD44 isoforms (CD44s, CD44v5
and CD44v10) apoptosis-associated markers (Bcl-2, Bax, and
Bcl-X), growth factors (TGF-a, C-erbB2 and VEGF), growth
factor receptors (EGF-R and Flt-1), tumour suppressor genes
(WT-1 and p27kip-1) and proliferation marker (MIB-1)].
Monoclonal antibody CD31
The primary monoclonal antibody CD31 (DAKO, A/S,
Glostrup, Denmark) was used for the assessment of
microvessels density (MVD) in tumour tissues. The
immunostaining procedure was similar to that of VEGF
[11] with the exception of digestion with 0.1% trypsin for
10 min at 37C to substitute antigen exposure enhancement
by microwave treatment.
Immunostaining analysis
The slides were examined at 259 magnification without
knowledge of the clinical outcome of the patients. Immu-
nostaining (nuclear, cytoplasmic or membranous) was
calculated as the percentage of positive cells in a particular
area: \10%; 10–25%; 25–50%; [50%. The specimens
were regarded stain positive when the percentage of posi-
tive cells was[10%. The expression of MIB-1, p27Kip1 and
microvessels density in cancer cells was evaluated sepa-
rately as described before [11, 12].
Statistical analysis
It was performed using the SPSS 11 software package. The
association between expression patterns of the various
factors and clinico-pathological features was analysed
using Pearson chi-square test. The associations between
normal kidney, MIB-1 and p27Kip1 PIs (proliferative indi-
ces) were studied using the Spearman rank correlation test
since the data were not normally distributed. The TGF-a,
EGF-R, VEGF and Flt-1 staining and their relationship
with CD31 counts were analysed by paired sample t-test.
Univariate analysis using the logrank test for trend was
performed. Multivariate analysis was performed using
Cox’s proportional hazards model with P \ 0.05 consid-
ered statistically significant.
Results
Clinicopathological findings of untreated
Wilms’ tumour
The patient’s distribution was 25 (58%) women and 18
(42%) men. The mean age at surgery was 4.2 years, and the
mean overall follow-up period was 11.9 years. The T-stage
distribution was stage 1 in 22, stage 2 in five, stage 3 in 11
patients, stage 4 in four and stage 5 in one. All the tumour
studied was of the classical triphasic type and did not
display any anaplastic features. All the patients had inter-
mediate risk tumours. Clinical progression occurred in
seven patients (16%). Five of patients show a relapse
within 3 months–2.2 years after initial diagnosis, while
two patients having a late relapse between 6.10 and
7.10 years. Two patients (5%) died from their tumour. At
the end of the follow-up period, 41 patients were alive.
Expression in untreated Wilms’ tumour tissue
Normal kidney tissue showed a positive staining of the
tubular epithelium for all the studied antibodies and was
used as an internal positive control. The percentage of
immunoreactive blastemal and epithelial cells in WT cases
are listed in Table 1. Blastemal and epithelial Bcl-X and
Bcl-2 were observed in the majority of cases. Expression of
blastemal CD44s and epithelial MIB-1 was seen in the
majority of cases. The other factors (CD44v5, CD44v10,
Bax, TGF-a, C-erbB2, VEGF, EGF-R, Flt-1, WT-1,
P27Kip-1) showed variable expression in tumour cells. The
blastemal and epithelial expressions of all the studied
markers were not correlated with clinico-pathological stage
of the disease.
MIB-1 and P27Kip-1 expression in untreated
Wilms’ tumours tissues
The mean percentage of MIB-1 and p27Kip1 positive cells
in normal renal tissue ranged between 1 and 14%
(3.4% ± 3.6) and 20–75% (53% ± 11.9), respectively.
While in WT tissues, the mean percentage of blastemal
and epithelial MIB-1 PI positive cells was 32.8% ± 27.8
(range 0–80%) and 34.1% ± 28.4 (range 0–85%),
respectively, whereas for blastemal and epithelial cells,
p27Kip1 was 34.8% ± 26 (range 1–90%) and 35% ± 26
(range 1–80%), respectively. Eight (19%) specimens,
taken from tumours of various stages, repeatedly showed
no labelling with MIB-1 antibody. According to the cut-
off point of 10%, MIB-1 positive blastemal and epithelial
cells were found in, respectively, 23 (54%) and 28 (65%)
of the WT studied. Also, p27Kip1 positive blastemal and
epithelial cells were found in 18 (42%) of the WT studied
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(Table 1). The proportion of MIB-1 positive cells relative
to p27Kip1 was greater in most specimens. Spearman rank
correlation coefficient estimation revealed no significant
correlation between blastemal and epithelial p27Kip1 PI
and MIB-1 PI.
MVD and its correlation with TGF-a, EGF-R, VEGF
and Flt-1 expression
Microvessels were defined by the presence of CD31-
stained capillaries or small clusters of CD31-positive cells.
Microvessel count ranged from 3 to 90 with a mean of 43.3
(SD, 30). The number of vessels counted in TGF-a, VEGF
and Flt-1 blastemal and epithelial positive tumours was
significantly greater than that in the negative tumours
(Table 2). EGF-R expression in the tumour cells did not
show a significant correlation with MVD, however. The
high vascularization foci occurred most frequently within
the tumour stroma. However, some cases were high in
MVD despite being TGF-a, EGF-R, VEGF and Flt-1
negative, and some cases were low in MVD although they
were TGF-a, EGF-R, VEGF and Flt-1 positive (data not
shown).
Prognostic value of these molecules
Univariate analysis using the logrank test for trend showed
a prognostic value of blastemal WT-1, TGF-a, VEGF,
MIB-1 and p27Kip1 expression for clinical progression.
Neither the epithelial expression of all markers studied nor
MVD did not show any prognostic value. A multivariate
Cox’ regression analysis was done using the stage, and
WT-1, TGF-a, VEGF, MIB-1 and p27Kip1 expression as
parameters. The parameters that were not dichotomic were
dichotomized as follows: stage 1, 2 versus stage 3, 4, 5;
immunoreactive score \ 10% versus [10% and MIB-1
was classified as PI \ 5% versus [5%; and for p27KIP1 as
PI \ 50% versus PI [ 50%. In that analysis, blastemal
WT-1 could be identified as an independent prognostic
marker for clinical progression.
Discussion
Wilms’ tumour is a malignant disease well known for its
unpredictable course and tendency of tumour recurrence or
metastasize, sometimes years after primary treatment [13,
14]. Since tumour metastasis is the principle cause of death
for cancer patients, there is consensus that a search for
tools that allow effective assessment of metastatic potential
of tumours is a primary goal for cancer research. It is well
established that preoperative chemotherapy can reduce the
morbidity [6]. The possibility that such therapy may
obscure or alter important prognostic features such as
anaplasia and pathologic stage, however, has remained a
concern [15, 16]. The aim of this study was to investigate
the expression of a broad panel of tumour markers at the
protein level in a group of specimens of untreated clinical
nephroblastoma, using paraffin-embedded tissue sections.
Results were compared with those obtained in a pretreated
group of patients.
The level of expression (intensity) or proportion of
positive cells was higher for most of the markers in the
untreated patients compared to the treated WT patients
(Table 1). The association between expression of prog-
nostic marker and the surgical stage could not be shown.
This is probably due to the disproportionate stage distri-
bution of the cases in this relatively small group of patients,
as 22 of the 43 cases (51%) were stage 1. In general, the
Table 2 Correlation between MVD and TGF-a, EGFR, VEGF and
Flt-1 expressions in untreated Wilms’ tumour group
MVD
Mean ± SD P value
TGF-a
Blastema
Negative 33.7 ± 29.3
Positive 53.2 ± 28.6 \0.05*
Epithelial
Negative 31.8 ± 30.2
Positive 52.3 ± 27.7 \0.05*
EGF-R
Blastema
Negative 39.9 ± 32.3
Positive 46.5 ± 28.6 [0.05*
Epithelial
Negative 41.7 ± 33.1
Positive 44.4 ± 28.7 [0.05*
VEGF
Blastema
Negative 28.5 ± 26.5 \0.05*
Positive 56.1 ± 27.9
Epithelial
Negative 26.7 ± 27.1 \0.05*
Positive 54.1 ± 27.7
Flt-1
Blastema
Negative 31.6 ± 27.5
Positive 54.4 ± 29.2 \0.05*
Epithelial
Negative 34.2 ± 31
Positive 53.7 ± 26.7 \0.05*
* t-test
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data of the preoperatively untreated group demonstrate that
the expression of most of the tumour markers has the same
trend for clinical progression as in the treated group studies
before [7–12]. In this series, no correlation between any
tumour markers and survival was demonstrated, as only 2
(5%) patients died of disease. Because of the difference
between SIOP and NWTS protocols, stage-for-stage out-
come comparisons between these two studies could not be
performed [17].
The mean percentage of blastemal and epithelial MIB-1
was higher in the untreated group when compared to the
treated group of patients. The contrary applies to the
P27Kip-1 expression, i.e. its expression level was lower in
the untreated compared to the treated group [12] (Table 1).
These observations confirmed previous studies correlating
proliferating cell nuclear antigen (PCNA) labelling scores
with the effect of therapy in WT [18]. In this study, it was
shown that chemotherapeutic manipulation of tissues
resulted in decreased PCNA staining in WT cell cultures
exposed to dexamethasone and cyclosporin A [19].
The expression of both Bcl-2 and Bax in untreated group
was similar to those reported for the preoperatively treated
group [9] (Table 1). Remarkably, in the untreated series,
Bcl-X expression was found in 88% of the tumours. These
results are similar to those reported for prostatic and gastric
cancer, in which Bcl-X immunoreactivity was found in 100
and 85% of the tumours, respectively [20, 21]. The per-
centage of Bcl-X was relatively high in comparison with
the preoperatively treated group, in which blastemal Bcl-X
immunoreactivity was found in only 38% of the tumours. It
is tempting to speculate that immunohistochemical
expression of the single marker, Bcl-X, might be a useful
parameter to predict chemo- or radiosensitivity of tumours
at the start of therapy (Table 1). Generally, chemotherapy
of WT leads to a selection of tumour cells, which are not in
cell cycle, because it knocks out the proliferative cohort of
cells. On the other hand, chemotherapeutical treatment may
also lead to an enhanced apoptotic response of tumour
cells. Such a response is determined by the expression of
various apoptotic proteins which either promotes (Bax,
Bcl-Xs) or block (Bcl-2, Bcl-XL) the potency of tumour
cells to undergo apoptosis. Strong expression of markers
that block the apoptotic process leads to drug resistance.
With regard to angiogenesis, TGF-a, VEGF and Flt-1
expression in tumour cells was significantly correlated with
the MVD in untreated WT. In general, in these patients, the
overall scores of the expression levels of TGF-a, VEGF
and Flt-1 in the blastemal and epithelial components were
higher, but these patients had a similar clinical outcome
compared to that in patients of the pretreatment group [11]
(Tables 1, 2). These results indicate that in untreated WT
counting of microvessels in the tumour shows correlation
with other angiogenic factors [22, 23].
In multivariate analysis, the tumour suppressor gene
product, WT-1, expressed by blastemal tissue in untreated
group, was the only independent prognostic marker for
clinical progression. The prognostic impact of WT-1
expression at the protein level was confirmed by a study
based on cDNA microarray analysis [24]. This is in con-
trast to the preoperatively treated group, in which blastemal
p27 was the strongest independent prognostic marker for
clinical progression [12]. This difference may be attributed
to the effect of chemotherapy, but the small number of
untreated cases and their skewed distribution of T-stage or
over-representation of stage I patients may also have
influenced this outcome.
In summary, most factors studied in a group of untreated
WT patients were expressed in the blastemal as well as in the
epithelial compartment. In contrast to the expression in
blastema, none of the epithelium-localized factors had any
prognostic value, however. Apparently, blastemal-bound
expression of particular markers has a much stronger prog-
nostic impact than their expression in the epithelium. How-
ever, future approaches in WT studies of the tumour marker
need to be multidisciplinary, biochemical, cytogenetic as
well as molecular genetic, optimally the usefulness of these
markers [25, 26]. So, WT patients might benefit from the
evaluation of these markers to more precisely estimate the
need for adjuvant chemotherapy and/or radiotherapy.
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